McIver Katharine A, Boveland Shannon D, Clark-Price Stuart C, Hofmeister Erik H
Department of Clinical Sciences, College of Veterinary Medicine, Auburn University, Auburn, AL, United States.
Front Vet Sci. 2023 Mar 6;10:1061755. doi: 10.3389/fvets.2023.1061755. eCollection 2023.
Anesthesia induction agents have the potential to cause severe ocular side effects, resulting in lasting damage to the eye.
The purpose of this study is to determine the effects of tiletamine-zolazepam on IOP compared to propofol when they are used as an induction agent in normal healthy dogs.
Twenty healthy adult client owned dogs weighing 22.2 ± 7.6 kg were selected for the study. In a randomized order, all dogs received tiletamine-zolazepam 5 mg/kg IV or propofol 8 mg/kg IV titrated to effect without premedication. Washout between each treatment was at least seven days. IOP measurements were obtained at four time points: baseline, post-induction, post-intubation, and after recovery using applanation tonometry. No additional procedures were performed. After normality of the data was determined, a linear mixed model was built with time, eye, treatment and all interactions of those variables as fixed effects and subject as a random effect.
There was no significant difference for age, body weight, drug dose, baseline IOP, and recovery IOP between treatments. Average IOP measurements remained within the normal range of 15-25 mmHg at these time points. However, IOP was significantly less elevated by the tiletamine-zolazepam treatment vs. propofol at the post-induction (mean difference: -4.7 ± 4.6 [95%CI -6.8 to -2.5]) and the post-intubation (mean difference: -4.4 ± 4.6 [95%CI -6.5 to -2.2]) time points.
Dogs receiving tiletamine-zolazepam for anesthetic induction had a significantly less elevated IOP at induction and intubation compared to dogs receiving propofol.
麻醉诱导剂有可能引起严重的眼部副作用,导致眼睛遭受永久性损伤。
本研究的目的是确定在正常健康犬中,将替来他明-唑拉西泮与丙泊酚用作诱导剂时,二者对眼压的影响。
选择20只体重为22.2±7.6千克的健康成年客户拥有的犬用于本研究。所有犬按随机顺序接受静脉注射5毫克/千克替来他明-唑拉西泮或静脉注射8毫克/千克丙泊酚,根据效果进行滴定,不进行术前用药。每次治疗之间的洗脱期至少为7天。使用压平眼压计在四个时间点测量眼压:基线、诱导后、插管后和恢复后。未进行其他操作。在确定数据呈正态分布后,建立线性混合模型,将时间、眼睛、治疗以及这些变量的所有相互作用作为固定效应,将个体作为随机效应。
治疗组之间在年龄、体重、药物剂量、基线眼压和恢复眼压方面无显著差异。在这些时间点,平均眼压测量值保持在15-25毫米汞柱的正常范围内。然而,在诱导后(平均差异:-4.7±4.6 [95%置信区间-6.8至-2.5])和插管后(平均差异:-4.4±4.6 [95%置信区间-6.5至-2.2])时间点,替来他明-唑拉西泮治疗组的眼压升高幅度明显低于丙泊酚治疗组。
与接受丙泊酚的犬相比,接受替来他明-唑拉西泮进行麻醉诱导的犬在诱导和插管时眼压升高幅度明显较小。